ライフサイエンスコーパス: FMT

1 FMT data were acquired concurrently with SPECT and CT da

2 FMT detected impaired recruitment of phagocytes and prot

3 FMT enhanced with ICG provided depth-resolved imaging of

4 FMT from a rationally selected donor reduced hospitaliza

5 FMT has also been used to treat other gastrointestinal (

6 FMT has been particularly effective for treating patient

7 FMT in patients with blood disorders is safe and promote

8 FMT induces remission in a significantly greater percent

9 FMT is a highly effective cure for RCDI, but increased k

10 FMT is a promising noninvasive molecular imaging approac

11 FMT is a promising treatment option for serious and recu

12 FMT is a tomographic optical imaging technique that, in

13 FMT is effective in the eradication of pathogenic antibi

14 FMT is emerging as a well-tolerated and effective treatm

15 FMT may have an additive benefit of reducing MDRO carria

16 FMT may help detect synovitis in patients with rheumatoi

17 FMT measurements can be done serially, with short imagin

18 FMT measurements of vascular fluorescent probes were lin

19 FMT reconstructions were coregistered with the MR images

20 FMT resulted in a resolution of symptoms that correlated

21 FMT was used to detect synovitis in all arthritic joints

22 FMT with antibiotic pretreatment was well tolerated.

23 FMT-randomized patients received 5 days of broad-spectru

24 FMT/CT imaging allows quantifying the biodistribution of

25 receive frozen (n = 114) or fresh (n = 118) FMT via enema.

26 s had a total of 11 SAEs compared to 2 (20%) FMT participants with SAEs (both FMT unrelated; P = 0.02

27 ticipants were randomly assigned to either a FMT group or a control group.

28 In addition, FMT imaging facilitates coregistration of the nuclear an

29 gational new drug (IND) permit to administer FMT for the purpose of conducting research or treating a

30 In younger adults, FMT signal in DCA was lower with age, likely related to

31 n the day prior to FMT to 8 (IQR, 7-9) after FMT administration for both overall and gastrointestinal

32 erformed on patients' stool before and after FMT and also on donors' stool.

33 n the impairment of intestinal barrier after FMT.

34 s) were taken at baseline, immediately after FMT and 3 months after FMT.

35 complete ARB decolonization at 1 month after FMT.

36 nd new medical conditions for 6 months after FMT.

37 ne, immediately after FMT and 3 months after FMT.

38 al supplementation with A. muciniphila after FMT with nonresponder feces restored the efficacy of PD-

39 Seven of the 9 patients in remission after FMT received fecal material from a single donor.

40 ) before surgery to 0.70 logMAR 1 year after FMT (2 lines gained; P = 0.000).

41 surgery, and remained improved 5 years after FMT with a median BCVA of 0.80 logMAR (1.5 lines gained

42 study, BCVA was improved up to 5 years after FMT.

43 y issues have hampered the development of an FMT capability at many hospitals.

44 On sensitivity analysis, FMT colonoscopy remained the most cost-effective strateg

45 ins in a state with decreased diversity, and FMT from a healthy individual restores the gut microbiot

46 nteers were screened as potential donors and FMT capsules were generated and stored at -80 degrees C

47 is to discuss the intestinal microbiota and FMT treatment of GI and non-GI diseases.

48 al contributions of antibiotic treatment and FMT to the observed results, the data suggest that FMT m

49 ently, there is growing interest in applying FMT to non-C difficile indications.

50 esearch and discuss hybrid protocols such as FMT-CT and PET-MRI.

51 e conduct and reporting of studies assessing FMT.

52 We assumed FMT delivery via colonoscopy as our base case, but condu

53 Resolution after autologous FMT differed by site (9 of 10 vs. 6 of 14 [P = 0.033]).

54 who developed recurrent CDI after autologous FMT were free of further CDI after subsequent donor FMT.

55 afe and was more efficacious than autologous FMT in preventing further CDI episodes.

56 ared with 15 of 24 (62.5%) in the autologous FMT group (P = 0.042).

57 5% CI, 47%-85%) after a single capsule-based FMT.

58 Herein, we combine a fiber-based FMT system with a preclinical SPECT/CT platform.

59 a wide range of disorders are needed before FMT can be accepted and applied clinically.

60 muscle, and tumor tissue correlated between FMT/CT and PET/MRI.

61 rochrome), we show good correlations between FMT and PET in probe concentration (r(2) > 0.99) and spa

62 ter-of-mass error of 2.68 +/- 1.0 mm between FMT and SPECT for axillary lymph node localization.

63 nter-of-mass error of 4.1 +/- 2.1 mm between FMT and SPECT measurements.

64 to 2 (20%) FMT participants with SAEs (both FMT unrelated; P = 0.02).

65 cin and metronidazole were both dominated by FMT colonoscopy.

66 us macaques received antibiotics followed by FMT.

67 reduced inflammation in infarcts measured by FMT-CT (fluorescence molecular tomography in conjunction

68 ompounds, and organ accumulation measured by FMT/CT and PET/MRI correlated significantly with ex vivo

69 h after injection, the mice were measured by FMT/CT and PET/MRI.

70 nificant change in the total number choosing FMT (154 [81%]; P = .15).

71 More respondents chose FMT if offered as a pill (90%; P = .002) or if their phy

72 ted kappa coefficient was used for comparing FMT and MR imaging semiquantitative scores, as well as a

73 An RCT comparing FMT route (n = 20) reported no difference between groups

74 One RCT comparing FMT with 2 control groups (n = 43) reported resolution o

75 tion that patients are unwilling to consider FMT because of its unappealing nature.

76 In contrast, FMT remains a purer measure of AADC function.

77 These coregistered FMT and SPECT/CT results with MOMIAs may facilitate the

78 We used partial volume-corrected FMT PET scans to measure age-related striatal dopamine s

79 Donor FMT restored gut bacterial community diversity and compo

80 e free of further CDI after subsequent donor FMT.

81 ysis, 20 of 22 patients (90.9%) in the donor FMT group achieved clinical cure compared with 15 of 24

82 in a lesion-based detection rate for d-(18)F-FMT and (18)F-FDG of 77% and 95%, respectively, with an

83 d-(18)F-FMT imaging in patients with NSCLC and HNSCC is safe and

84 nsitivity but higher specificity for d-(18)F-FMT over (18)F-FDG, since there is no d-(18)F-FMT uptake

85 -FDG PET/CT scans within 21 d before d-(18)F-FMT PET/CT.

86 A high d-(18)F-FMT tumor-to-blood pool ratio had a negative correlation

87 MT over (18)F-FDG, since there is no d-(18)F-FMT uptake in inflammation.

88 (D)-(18)F-fluoromethyltyrosine (d-(18)F-FMT), or BAY 86-9596, is a novel (18)F-labeled tyrosine

89 nd only 2 false-positive lesions for d-(18)F-FMT, whereas (18)F-FDG was true-positive in 42 lesions,

90 f the 42 malignant lesions were also d-(18)F-FMT-positive, and 10 lesions had no tracer uptake above

91 e reactions were observed related to d-(18)F-FMT.

92 st, there was no relationship between [(18)F]FMT and methylphenidate-induced [(11)C]raclopride displa

93 vealed a positive correlation between [(18)F]FMT Ki and the baseline (placebo) [(11)C]raclopride meas

94 ) using 6-[(18)F]fluoro-l-m-tyrosine ([(18)F]FMT; a substrate for aromatic amino acid decarboxylase),

95 Following FMT, there were variable shifts in faecal and mucosal mi

96 (n = 3) and patients prior to and following FMT.

97 her define the microbiota recovery following FMT.

98 iven the lack of clinical response following FMT via a single nasogastric administration our results

99 was assessed before and four weeks following FMT.

100 ned in recipients for up to a year following FMT.

101 Patients were considered for FMT if they had low vision in the fellow eye and choroid

102 2011 and 2014 to determine risk factors for FMT failure.

103 ich increases the availability of faeces for FMT and decreases the cost of screening individual donor

104 ); 77% were willing to pay out-of-pocket for FMT.

105 cent studies have shown the success rate for FMT as treatment for recurrent CDI being greater than 90

106 opulation and 178 (frozen FMT: n = 91, fresh FMT: n = 87) in the per-protocol population.

107 the frozen FMT group and 85.1% for the fresh FMT group (difference, -1.6% [95% CI, -10.5% to infinity

108 the frozen FMT group and 70.3% for the fresh FMT group (difference, 4.7% [95% CI, -5.2% to infinity];

109 he frozen FMT group and n = 111 in the fresh FMT group) were included in the modified intention-to-tr

110 y CDI, the use of frozen compared with fresh FMT did not result in worse proportion of clinical resol

111 MT, 16 respondents changed their choice from FMT to antibiotics alone, but there was no significant c

112 Fluorochrome concentrations derived from FMT measurements were reconstructed with an accuracy of

113 n-to-treat (mITT) population and 178 (frozen FMT: n = 91, fresh FMT: n = 87) in the per-protocol popu

114 the potential advantages of providing frozen FMT, its use is a reasonable option in this setting.

115 clinical resolution was 75.0% for the frozen FMT group and 70.3% for the fresh FMT group (difference,

116 clinical resolution was 83.5% for the frozen FMT group and 85.1% for the fresh FMT group (difference,

117 total of 219 patients (n = 108 in the frozen FMT group and n = 111 in the fresh FMT group) were inclu

118 ests of frontal lobe function showed greater FMT signal in right DCA, independent of age effects.

119 Within the older group, FMT signal in dorsal caudate (DCA) and dorsal putamen wa

120 However, FMT increased diversity and beneficial taxa.

121 neated with the aid of repeated PET imaging (FMT and sodium fluoride for bone), realignment to subseq

122 Importantly, FMT from RIP140mvarphiKD to WT not only effectively tran

123 is review summarizes therapeutic advances in FMT, latest FMT therapies and presents the potential of

124 rors in planar imaging but only 20% error in FMT, thus confirming tomographic imaging as a preferred

125 man physiology, and microbiota being used in FMT represents a new class of therapeutics.

126 ined and a treatment algorithm incorporating FMT is described.

127 re unlikely to benefit from VEGF inhibitors, FMT can be considered for second eyes with neovascular A

128 zed with ARB were treated with intraduodenal FMT according to a prospective protocol (NCT02461199).

129 mmarizes therapeutic advances in FMT, latest FMT therapies and presents the potential of FMT therapeu

130 Five SOC and no FMT participants developed further HE (P = 0.03).

131 The administration of FMT immediately after vancomycin cleared C. difficile an

132 tion of diarrhea following administration of FMT using frozen encapsulated inoculum from unrelated do

133 sed patient perceptions of the aesthetics of FMT and their willingness to consider it as a treatment

134 Respondents rated all aspects of FMT at least "somewhat unappealing," selecting "the need

135 Women rated all aspects of FMT more unappealing; older respondents rated all aspect

136 most important methodological components of FMT and inability to assess the actual conduct of studie

137 Key components of FMT interventions, which are necessary to replicate and

138 We assessed the effects of FMT on microbiota composition and function, mucosal immu

139 The effects of FMT on recipient microbiota in inflammatory bowel diseas

140 The effects of FMT on the gut microbiota community were detectable in r

141 acteriophages mediate many of the effects of FMT, and that FFT might be an alternative approach, part

142 studies assessing the safety or efficacy of FMT.

143 The amplitude of the loss of FMT uptake in striatum at 4 weeks with either model was

144 When aware of the fecal nature of FMT, 16 respondents changed their choice from FMT to ant

145 cognize the inherently unappealing nature of FMT, but they are nonetheless open to considering it as

146 the transplanted material on the outcome of FMT.

147 ay to determine the therapeutic potential of FMT in other conditions, particularly inflammatory bowel

148 The commercial potential of FMT is being explored with several products under develo

149 FMT therapies and presents the potential of FMT therapeutics in other gastrointestinal and extra-int

150 ntly, the FDA determined that prescribers of FMT must possess an approved investigational new drug (I

151 priori information in the reconstruction of FMT data integrated both optical and nuclear contrasts.

152 MT was associated with a significant risk of FMT failure (odds ratio, 0.15; 95% confidence interval,

153 is needed to understand the possible role of FMT in these other conditions.

154 The primary outcome was safety of FMT compared to SOC using FMT-related serious adverse ev

155 We assessed the efficacy and safety of FMT for patients with UC in a double-blind randomized tr

156 ive: To determine the efficacy and safety of FMT for treatment of recurrent CDI.

157 a preclinical demonstration of the safety of FMT in primates infected with a lentivirus, this study p

158 IV infection, determination of the safety of FMT is crucial to prevent deleterious consequences if it

159 Semiquantitative scoring of FMT correlated well with MR imaging findings (weighted k

160 his review, we highlight clinical studies of FMT for treatment of recurrent CDI and discuss the safet

161 Any study of FMT to treat adult patients with CDI; case reports were

162 The success of FMT in curing Clostridium difficile infection (CDI) is w

163 maintenance, as well as controlled trials of FMT in a wide range of disorders are needed before FMT c

164 s and series, document the successful use of FMT for treatment of RCDI in the past 2 years.

165 literature unequivocally supports the use of FMT in treating relapsing CDI.

166 The use of FMT is a successful treatment for recurrent CDI when pri

167 Although an IND is not required for use of FMT to treat RCDI, an IND is strongly encouraged and may

168 when the study began and during each week of FMT for microbiome analysis.

169 On FMT, Prosense-680 infarct signal was 19-fold higher than

170 Evidence is insufficient on FMT for refractory or initial CDI treatment and on wheth

171 macaque model of HIV infection and performed FMT on six chronically SIV-infected rhesus macaques on a

172 We performed FMT imaging to compare the course of efficient and impai

173 stantibiotics, but reverted to baseline post-FMT.

174 decreased activation of CD4(+) T cells post-FMT, and these changes correlated most strongly across a

175 activation in gastrointestinal tissues post-FMT.

176 terial community composition at 2 weeks post-FMT resembled the pre-FMT community structure, although

177 sition at 2 weeks post-FMT resembled the pre-FMT community structure, although differences in the abu

178 re to use an oral vancomycin taper preceding FMT was associated with a significant risk of FMT failur

179 robiota suspension), a commercially prepared FMT drug manufactured using standardized processes and a

180 The reconstructed quantitative FMT signal, denoting synovial hyperperfusion, was used t

181 The fiber-based, video-rate FMT imaging system is composed of 12 sources (785- and 8

182 ity of integrating a fiber-based, video-rate FMT system with a commercial preclinical SPECT/CT platfo

183 Most respondents preferred to receive FMT in the hospital (48%) or physician's office (39%); 7

184 only, 162 respondents (85%) chose to receive FMT, and 29 (15%) chose antibiotics alone.

185 study, patients with RCDI (n = 20) received FMT from universal donors via colonoscopy.

186 re randomly assigned to groups that received FMT (50 mL, via enema, from healthy anonymous donors; n

187 Nine patients who received FMT (24%) and 2 who received placebo (5%) were in remiss

188 ng "the need to handle stool" and "receiving FMT by nasogastric tube" as most unappealing.

189 Stool from patients receiving FMT had greater microbial diversity, compared with basel

190 case-series studies (516 patients receiving FMT) reported using FMT for patients with recurrent CDI.

191 The reconstructed FMT signal correlated with MR imaging findings in intens

192 ta than exist currently, as well as refining FMT beyond current "whole-stool" transplants to increase

193 However, there were no significant FMT-induced metabolic or immunological changes, or benef

194 achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the

195 ctrum antibiotic pretreatment, then a single FMT enema from the same donor with the optimal microbiot

196 adults showed significantly greater striatal FMT signal than younger adults.

197 Our data suggest that higher striatal FMT signal represents nonoptimal dopamine processing.

198 We also investigated how striatal FMT signal related to a cognitive measure of frontal lob

199 In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is eff

200 fluorescence-mediated tomographic technique (FMT) that enables rapid measurements of fluorochrome-bas

201 We conclude that FMT can transfer not only microbiota but also the donors

202 egies for recurrent CDI, we demonstrate that FMT colonoscopy is the most cost-effective initial strat

203 There is hope that FMT may eventually prove beneficial for the treatment of

204 The findings also suggest that FMT can serve as a surrogate modality for the screening

205 ed data from over 500 CDI cases suggest that FMT is generally well tolerated with minimal side effect

206 the observed results, the data suggest that FMT may have beneficial effects that should be further e

207 tric administration our results suggest that FMT/bacteriotherapy for pouchitis patients requires furt

208 one randomized clinical trial suggests that FMT is able to restore the wide diversity of microflora,

209 thogenesis has led to the understanding that FMT promotes intestinal ecological restoration and highl

210 The FMT group received two training sessions/ week for 3 mon

211 The FMT group showed greater improvements than the controls

212 The FMT-CT on Day 5 after MI showed higher proteolysis and p

213 ging systems can potentially accommodate the FMT fiber imaging arrays.

214 progression in individual rats, although the FMT is not a sensitive ligand to monitor the extent of t

215 ed out from the placebo group and 2 from the FMT group).

216 2 weeks, the microbiota of responders in the FMT group was similar to that of their healthy donors; r

217 erse events occurred in 4 patients (2 in the FMT group), but these were not considered to be related

218 Cognition improved in the FMT, but not the SOC, group.

219 ndicated that the balance performance of the FMT group was significantly better than that of the cont

220 f important methodological components of the FMT intervention.

221 tion of symptoms in 81%, 31%, and 23% of the FMT, vancomycin, or vancomycin-plus-bowel lavage groups,

222 ning, stool preparation, and delivery of the FMT.

223 ese were not considered to be related to the FMT.

224 Therapeutic FMT is a dynamic field with new and emerging indications

225 tients, and fully characterized according to FMT standards.

226 No serious adverse events attributed to FMT were observed.

227 quartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion.

228 testinal-specific health on the day prior to FMT to 8 (IQR, 7-9) after FMT administration for both ov

229 There were no SAEs related to FMT.

230 iber-based fluorescence-mediated tomography (FMT) systems provide a viable solution.

231 f advanced fluorescence-mediated tomography (FMT)/CT in comparison to PET/MRI for quantitative analys

232 surements [fluorescence-mediated tomography (FMT)] show exquisite congruence to radionuclide measurem

233 tected by fluorescence molecular tomography (FMT) combined with micro-computed tomography (CT).

234 ltichannel fluorescent molecular tomography (FMT) for spatiotemporal resolution of phagocytic and pro

235 -enhanced fluorescence molecular tomography (FMT) system and 3-T MR imaging as the standard of refere

236 solved by fluorescence molecular tomography (FMT) with a phosphatidylserine-sensing fluorescent probe

237 approach: fluorescence molecular tomography (FMT).

238 ion using fluorescence molecular tomography (FMT).

239 mensional fluorescence molecular tomography (FMT).

240 ninvasive fluorescence molecular tomography (FMT-CT) and physiologic imaging (magnetic resonance imag

241 ance training (functional-movement training, FMT) programme in improving balance deficits in a DCD po

242 the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from un

243 view the use of fecal microbiota transplant (FMT) in the treatment of pediatric RCDIs.

244 Fecal microbiota transplant (FMT) is a highly efficacious treatment for recurrent CDI

245 idaxomicin, and fecal microbiota transplant (FMT).

246 nt data on fecal microbiota transplantation (FMT) and critically discuss potential advantages and han

247 fficacy of fecal microbiota transplantation (FMT) as a potential therapeutic in HIV-infected individu

248 articular, fecal microbiota transplantation (FMT) as a treatment strategy is outlined and a treatment

249 he use of faecal microbiota transplantation (FMT) as treatment for recurrent Clostridium difficile in

250 ction with fecal microbiota transplantation (FMT) at a tertiary referral center between 2011 and 2014

251 Fecal microbiota transplantation (FMT) could be a novel treatment option for several chron

252 sized that fecal microbiota transplantation (FMT) could be used to eradicate ARB in humans.

253 he role of fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) is not we

254 success of fecal microbiota transplantation (FMT) for recurrent CDI.

255 effects of fecal microbiota transplantation (FMT) for ulcerative colitis (UC).

256 Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into ger

257 Fecal microbiota transplantation (FMT) has been demonstrated to durably alter the gut micr

258 Fecal microbiota transplantation (FMT) has been shown to be a superior therapeutic modalit

259 Fecal microbiota transplantation (FMT) has been shown to be effective in treating relapsin

260 Faecal microbiota transplantation (FMT) has been used for more than five decades to treat a

261 Faecal microbiota transplantation (FMT) has undergone dramatic progression over the past ye

262 fficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI)

263 Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent CDI, ye

264 Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostri

265 ND & AIMS: Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostri

266 Fecal microbiota transplantation (FMT) is a promising, but not readily available, interven

267 Fecal microbiota transplantation (FMT) is an alternative approach that induced remission i

268 Faecal microbiota transplantation (FMT) is effective in the treatment of Clostridium diffic

269 Fecal microbiota transplantation (FMT) may improve dysbiosis; however, it has not been stu

270 While fecal microbiota transplantation (FMT) presents an attractive therapeutic strategy, it rem

271 OF REVIEW: Fecal microbiota transplantation (FMT) re-establishes a balanced intestinal flora with res

272 e in which fecal microbiota transplantation (FMT) utilized for relapsing Clostridium difficile coliti

273 s and that fecal microbiota transplantation (FMT) would reduce the number of antibiotic-resistant gen

274 Fecal microbiota transplantation (FMT), a safe, effective alternative therapy for recurren

275 sed use of fecal microbiota transplantation (FMT).

276 T) radiotracer 6-[(18)F]fluoro-l-m-tyrosine (FMT) is a substrate of the dopamine-synthesizing enzyme,

277 e PET ligand was 6-[18F]fluoro-L-m-tyrosine (FMT), imaged prior to, and at two intervals after initia

278 ng with the tracer [(18)F]fluoro-m-tyrosine (FMT), the recovery of enzyme activity after suicide inhi

279 been reported in children who have undergone FMT.

280 ough 2012, a total of 255 patients underwent FMT.

281 = 50) were assigned to groups that underwent FMT with feces from healthy donors or were given autolog

282 y obtain an IND before they can begin to use FMT as part of their clinical practice.

283 es, initial treatment of recurrent CDI using FMT colonoscopy was the most cost-effective strategy, wi

284 We confirmed using FMT from HFD-fed RIP140mvarphiKD to wild type (WT) mice

285 (516 patients receiving FMT) reported using FMT for patients with recurrent CDI.

286 come was safety of FMT compared to SOC using FMT-related serious adverse events (SAEs).

287 Specifically, we show that in vivo FMT detects impaired healing in FXIII-/- mice.

288 In vivo FMT imaging showed tumor accumulation and excellent tumo

289 ively (P < 0.001 for both control groups vs. FMT).

290 CLIO-VT750 FMT signal coregistered with contrast enhancement in the

291 In clinical settings where FMT is not available or applicable, the preferred strate

292 antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so.

293 We aimed to define whether FMT using a rationally derived stool donor is safe in re

294 ciples that underlie the mechanisms by which FMT shows therapeutic efficacy in CDI are becoming appar

295 ate the potential of HS680 and combined with FMT imaging to non-invasively quantify CA IX expression

296 26 colon tumor-bearing mice were imaged with FMT after intravenous administration of long-circulating

297 Among 7 patients treated with FMT for initial CDI, results were mixed.

298 Conversely, mice not treated with FMT remained persistently colonized with high levels of

299 chitis (current PDAI >/=7) were treated with FMT via nasogastric administration.

300 riteria were patients younger than 60 years, FMT for disease other than AMD, and a follow-up of less